Genmab — December 2019
-
-
Har den været her (TKD-079) https://twitter.com/Abdallah81MD/status/1203382881881595904
-
God morgen.

-
God morgen

-
Jeg købte i 1470 i fredags
Personligt tror jeg vi har ramt bunden, for nu. -
I forbindelse med Peter12's link i aftes 21.46. ang. TAK-079. Skriver MD. Ola A Abdallah. - Those who are anti- CD 38 therapy naive the ORR was 46%. I dont think that TAK-079 will add anything new If it don't show any benefit over Daratumumab or at least to show some response RR for those who are refractory to daratumumab. - det tyder da ikke på at han er overvældet af TAK-079. ?? Eller har jeg misforstået det. ?!
-
Bibob jeg sad også og læste lidt op på TAK i går, jeg har ikke vendt det med eksperten derhjemme endnu, men jeg er ikke overvældet over deres data endnu. Men som dig er jeg heller ikke sikker på jeg har indfanget det hele, men det finder jeg snart ud af:-)
-
Genmab's Commercial Engine Aspirations
Jan G. J. van de Winkel, Ph.D., cofounder and CEO of Genmab, discusses the company’s aspirations to eventually commercialize its own products....
(www.lifescienceleader.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind